Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression
An adequate blood supply is essential for cancer cells to survive and grow; thus, the concept of inhibiting tumor angiogenesis has been applied to cancer therapy, and several drugs are already in clinical use. It has been shown that treatment with those anti-angiogenic drugs improved the response ra...
Main Authors: | Hisatsugu Goto, Yasuhiko Nishioka |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/19/1/98 |
Similar Items
-
Significance of anti-angiogenic therapy in head and neck cancer—Heterogeneity of tumor endothelium
by: Kyoko Hida, et al.
Published: (2010-02-01) -
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
by: Seidai Sato, et al.
Published: (2017-09-01) -
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
by: Wioletta Olejarz, et al.
Published: (2020-08-01) -
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
by: Iris Uribesalgo, et al.
Published: (2019-08-01) -
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
by: Panagiotis Ntellas, et al.
Published: (2020-10-01)